COMMITMENTS AND CONTINGENCIES - Employment Agreement (Details) - USD ($)									1 Months Ended			12 Months Ended
	Nov. 01, 2021	Oct. 03, 2020	Dec. 05, 2019	Dec. 27, 2018	Jul. 28, 2018	May 02, 2018	Mar. 15, 2018	Jul. 28, 2017	Oct. 31, 2021	Sep. 30, 2019	Jul. 28, 2017	Sep. 30, 2021	Mar. 02, 2021	Oct. 19, 2020
COMMITMENTS AND CONTINGENCIES
Revenue bonus recorded to long term accrued liabilities													$ 556,840
Employment Agreement [Member] | CEO
COMMITMENTS AND CONTINGENCIES
Annual base salary		$ 400,000
One-time discretionary bonus awarded														$ 250,000
Approved bonus			$ 803,623	$ 553,623		$ 403,623	$ 121,125
Threshold revenue for two consecutive quarters							3,000,000
Threshold revenue for fiscal year							$ 12,000,000
Number of shares granted	300,000
Revenue bonus recorded to long term accrued liabilities	$ 300,000
Employment Agreement [Member] | CEO | Minimum
COMMITMENTS AND CONTINGENCIES
Threshold annual revenue										$ 300,000
Employment Agreement [Member] | CEO | Maximum
COMMITMENTS AND CONTINGENCIES
Threshold annual revenue												$ 8,000,000
Employment Agreement [Member] | CEO | Subsequent event
COMMITMENTS AND CONTINGENCIES
Annual base salary									$ 450,000
New Employment Agreement | CEO
COMMITMENTS AND CONTINGENCIES
Agreement renewal period											1 year
Special cash incentive bonus											$ 800,000
Special cash incentive bonus payable on completing threshold annual revenue								$ 300,000			300,000
Threshold annual revenue								8,000,000			8,000,000
Special cash incentive bonus payable on completing threshold annual revenue in excess of first threshold								$ 100,000			100,000
Threshold annual revenue in excess of first threshold											2,000,000
Annual base salary											$ 400,000
Compensation Description					The agreement with Dr. Hayward also provides that if he is terminated before the end of the initial or a renewal term by the Company without cause or if Dr. Hayward terminates his employment for good reason, then, in addition to previously earned and unpaid salary, bonus and benefits, and subject to the delivery of a general release and continuing compliance with restrictive covenants, Dr. Hayward will be entitled to receive a pro rata portion of the greater of either (X) the annual bonus he would have received if employment had continued through the end of the year of termination or (Y) the prior year's bonus; salary continuation payments for two years following termination equal to the greater of (i) three times base salary or (ii) two times base salary plus bonus; company-paid COBRA continuation coverage for 18 months post-termination; continuing life insurance benefits (if any) for two years; and extended exercisability of outstanding vested options (for three years from termination date or, if earlier, the expiration of the fixed option term). If termination of employment as described above occurs within six months before or two years after a change in control of the Company, then, in addition to the above payments and benefits, all of Dr. Hayward's outstanding options and other equity incentive awards will become fully vested and Dr. Hayward will receive a lump sum payment of the amounts that would otherwise be paid as salary continuation. In general, a change in control will include a 30% or more change in ownership of the Company.